90
Participants
Start Date
July 7, 2020
Primary Completion Date
December 28, 2022
Study Completion Date
December 28, 2022
BAY1097761 Active Dose 1
Participants will receive a lower dose ADM by inhalation
Placebo to BAY1097761
Participants will receive Placebo to BAY1097761 by inhalation
BAY1097761 Active Dose 2
Participants will receive a higher dose ADM by inhalation
Universitätsklinikum AKH Wien, Vienna
Medizinische Universität Innsbruck, Innsbruck
Fakultni nemocnice Kralovske Vinohrady, Prague
Hôpital du Nord - Marseille, Marseille
Istituto Clinico Humanitas - Humanitas Mirasole S.p.A., Milan
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan
ASST Santi Paolo e Carlo, Milan
Universitätsklinikum Schleswig-Holstein (UKSH), Kiel
Klinikum Oldenburg AöR, Oldenburg
Center Hospitalier Michallon - Grenoble, La Tronche
Centre Hospitalier Universitaire - Angers, Angers
Klinikum der Stadt Köln gGmbH - Krankenhaus Merheim, Cologne
Hôpital Civil - Strasbourg, Strasbourg
Hôpital de la Pitié-Salpétrière, Paris
Cochin - Paris, Paris
Fakultni nemocnice v Motole, Prague
Masaryk Hospital Usti n/L, Ústí nad Labem
Corporació Sanitària Parc Taulí, Sabadell
Ciutat Sanitaria i Universitaria de la Vall d'Hebron, Barcelona
Hospital de la Santa Creu i de Sant Pau, Barcelona
University Hospital of Wales, Cardiff
Guy's Hospital, London
Lead Sponsor
Bayer
INDUSTRY